Endoscopic findings can predict the efficacy of leukocytapheresis for steroid-naive patients with moderately active ulcerative colitis.
OBJECTIVE
To investigate the therapeutic usefulness of leukocytapheresis (LCAP; Cellsoba) in steroid-naive patients with moderately active ulcerative colitis (UC).


METHODS
Eighteen steroid-naive patients with moderately active UC received one LCAP session every week for five consecutive weeks.


RESULTS
The remission rate 8 weeks after the last LCAP session was 61.1% (11/18). All three patients with deep ulcers showed worsening after LCAP. For the remaining 15 patients, who had erosions or geographic ulcers, the average clinical activity index (CAI) score dropped significantly from 9.4 to 3.8 eight weeks after the last LCAP session (t = 4.89, P = 0.001). The average C-reactive protein (CRP) levels before and after LCAP were 1.2 mg/dL and 1.0 mg/dL, respectively. Of the patients with erosions, geographic ulcers, and deep ulcers, 100% (9/9), 33.3% (2/6), and 0% (0/3) were in remission 8 weeks after the last LCAP session, respectively (chi(2) = 7.65, P < 0.005). Forty-eight weeks after the last LCAP session, the remission rates for patients with erosions and geographic ulcers were 44.4% (4/9) and 16.7% (1/6), respectively. Only one patient suffered a mild adverse event after LCAP (nausea).


CONCLUSIONS
LCAP is a useful and safe therapy for steroid-naive UC patients with moderate disease activity. Moreover, the efficacy of the treatment can be predicted on the basis of endoscopic findings.
Umehara
Yasushi
Y
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Kinki University School of Medicine, 377-2 Ohno-Higashi, Osaka-Sayama 589-8511, Japan.
Kudo
Masatoshi
M
Kawasaki
Masanori
M
D000328:Adult; D002097:C-Reactive Protein / Q000378:metabolism; D003093:Colitis, Ulcerative / Q000188:drug therapy / Q000473:pathology / Q000628:therapy*; D003113:Colonoscopy; D005260:Female; D006801:Humans; D007937:Leukapheresis; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D012074:Remission Induction; D013256:Steroids / Q000627:therapeutic use
D013256:Steroids; D002097:C-Reactive Protein
Gut. 1960 Sep;1:217-22
13760840
N Engl J Med. 1994 Jun 30;330(26):1841-5
8196726
Gastroenterology. 1983 Aug;85(2):351-7
6305758
Am J Gastroenterol. 2004 Jul;99(7):1371-85
15233681
Scand J Gastroenterol. 1978;13(7):833-7
364626
World J Gastroenterol. 2006 Apr 14;12(14):2201-4
16610021
J Gastroenterol. 1995 Jun;30(3):322-9
7647899
Ther Apher. 2001 Aug;5(4):287-92
11724514
Aliment Pharmacol Ther. 1998 Oct;12(10):973-8
9798801
Am J Gastroenterol. 2000 Aug;95(8):2000-8
10950049
Ther Apher. 1998 May;2(2):90-2
10225705
Gastroenterology. 2001 Aug;121(2):255-60
11487534
Curr Pharm Des. 2003;9(4):307-21
12570823
N Engl J Med. 1991 Sep 26;325(13):928-37
1881418
J Clin Gastroenterol. 1995 Jun;20(4):285-9
7665815
N Engl J Med. 1996 Mar 28;334(13):841-8
8596552
Dig Dis Sci. 2007 Sep;52(9):2044-53
17410456
Gastroenterology. 1981 Dec;81(6):1115-24
7286589
Gastroenterology. 2001 May;120(6):1323-9
11313301
Ther Apher. 2002 Aug;6(4):261-6
12164794
Gut. 1983 Mar;24(3):177-81
6337933
Inflamm Bowel Dis. 2004 May;10(3):251-7
15290920
Br Med J. 1962 Aug 18;2(5302):441-3
13865152
Lancet. 1974 Jun 1;1(7866):1067-70
4135487
N Engl J Med. 2002 Aug 8;347(6):417-29
12167685
Aliment Pharmacol Ther. 2004 Dec;20(11-12):1347-52
15606397
Ther Apher. 2002 Aug;6(4):255-60
12164793
Gastrointest Endosc. 2001 Jun;53(7):816-8
11375602
Gastroenterology. 1985 Nov;89(5):1005-13
3930339
Dig Dis Sci. 1998 Sep;43(9):2071-9
9753275